期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

聚乙二醇干扰素α治疗核苷(酸)类似物经治慢性乙型肝炎患者专家会议纪要 被引量：4

Symposium on treatment of patients with chronic hepatitis B who have an initial nucleos(t)ide analogues therapy with pegylated interferon α
原文传递
导出
摘要 随着对慢性乙型肝炎(CHB)抗病毒治疗研究的深入以及临床对CHB治疗经验的积累,越来越多的患者接受了抗病毒治疗.对于经过核苷(酸)类似物(NAs)规范治疗后未能获得病毒学或血清学应答,或在治疗中出现耐药以及达到治疗目标后停药复发的患者往往需要调整治疗策略.如何在这部分NAs经治患者中实现理想的治疗目标已成为临床关注的热点,包括如何通过治疗策略的调整达到理想的治疗目标,如何实现停药后持久应答,以及如何对长期应用NAs应答不佳或者出现耐药的患者调整治疗方案等,仍是临床上尚未解决的问题.
作者 无
机构地区 聚乙二醇干扰素α治疗核苷(酸)类似物经治慢性乙型肝炎专家组
出处 《中华临床感染病杂志》 CAS 2013年第4期193-196,共4页 Chinese Journal of Clinical Infectious Diseases
关键词 肝炎 乙型 慢性 干扰素Α 核苷(酸)类似物 再治疗
分类号 R [医药卫生]
  • 相关文献

参考文献12

  • 1Ning Q,Han MF,Sun YT. New treatment strategy:switching from long-term entecavir to peginterferon alfa-2a induces HBeAg seroconversion/HBsAg clearance in patients with HBeAgpositive chronic hepatitis B[J].Hepatology,2012,(Suppl 1):216A.
  • 2Trung TB,Phiet PH. Peginterferon alfa-2a monotherapy as a strategy for achieving sustained response in patients SWITCHED from longterm nucleos(t) ide analog therapy:the results of 1 year follow up[J].Hepatology,2011.1403A.
  • 3Ouzan D,Penaranda G,Joly H. Add-on of peg interferon to a stable nucleoside regimen led to loss of HbsAg in chronic hepatitis HBeAg negative patients[J].Hepatology,2012,(Suppl 1):465A.
  • 4Kittner JM,Sprinzl MF,Grambihler A. Adding pegylated interferon to a current nucleos (t) ide therapy leads to HBsAg seroconversion in a subgroup of patients with chronic hepatitis B[J].Journal of Clinical Virology,2012.93-95.
  • 5Li Q,Dong G,Yu J. Adding peginterferon alfa-2a on nucleos(t) ide analogues therapy improves HBeAg seroconversion and HBsAg decline in HBeAg-positive chronic hepatitis B patients who have achieved virological responses[J].Journal of Hepatology,2013,(Suppl 1):S307.
  • 6Chen XF,Chen XP,Ma XJ. Optimized strategy:sequential pegylated interferon α-2a therapy in entecavir-treated patients CHB without satisfactory end-point led to HBeAg seroconversion[J].Journal of Hepatology,2013,(Suppl 1):S300.
  • 7Wu ZW,Sheng JF,Li LJ. Improvement of HBsAg loss by additional Peg-IFN in nucleosides analogs treated chronic hepatitis B patients[J].Hepatology,2012,(Suppl 1):430A.
  • 8Xu DZ,Xie Y,Wei L. Efficacy and safety of peginterferon alfa-2a in Chinese patients with HBeAg-postitive chronic hepatitis B[J].Journal of Hepatology,2008,(Suppl 2):S266.
  • 9Sun J,Hou JL,Xie Q. Randomised clinical trial:effi cacy of peginterferon alfa-2a in HBeAg positive chronic hepatitis B patients with lamivudine resistance[J].Alimentary Pharmacology and Therapeutics,2011.424-431.
  • 10岳伟,袁宏,毛小荣,邓永东,陈琳.不同策略治疗rtN236T位点变异的HBeAg阳性慢性乙型肝炎的疗效观察[J].中华肝脏病杂志,2013,21(3):184-188. 被引量：14

二级参考文献9

  • 1田玉岭,赵伟,沈玲,刘伟,常家宝,方之勋,殷卫卫,王雷,孙溪宾,杨毅军.聚乙二醇化干扰素α-2a治疗慢性乙型肝炎的临床研究[J].中华肝脏病杂志,2006,14(11):806-810. 被引量：17
  • 2Marcellin P, Chang TT, Lim SG, et al. Long-term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen- positive chronic hepatitis B. Hepatology, 2008, 48: 750-758.
  • 3Lau GK, Piratvisuth T, Luo KX, et al. Peginterferon Alfa-2a, lamivudin, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med, 2005, 352: 2682-2695.
  • 4Takkenberg B, Zaaijer HL, Weegink C, et al. High rate of HBsAg loss and HBsAg seroconversion in chronic hepatitis B patients on combination therapy with peginterferon alfa-2a (Pegasys) and adefovir (Hepsera): HBsAg titer predicts HBsAg loss or Hepatology, 2008, 48 Suppl 1: 1026A.
  • 5Werle-Lapostolle B, Bowden S, Locamini S, et al. Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. Gastroenterology, 2004,126: 1750-1758.
  • 6贾继东,郑欢伟.干扰素在治疗慢性乙型肝炎中的应用[J].中华肝脏病杂志,2007,15(11):849-850. 被引量：11
  • 7杨松,温少芳,闫杰.乙型肝炎病毒耐药专家共识:2009年更新[J].中华实验和临床感染病杂志（电子版）,2009,3(1):43-47. 被引量：63
  • 8贾继东,李兰娟.慢性乙型肝炎防治指南（2010年版）[J].中华肝脏病杂志,2011,19(1):13-24. 被引量：3213
  • 9中华医学会传染病与,寄生虫病学分会,肝病学分会.病毒性肝炎防治方案[J].中华肝脏病杂志,2000,8(6):324-329. 被引量：14005

共引文献13

同被引文献31

  • 1王磊,闫杰,张照华,王晶波,杜以真,李晓迎,王耀宗.拉米夫定治疗慢性乙型肝炎患者YMDD变异及影响因素的研究[J].中华肝脏病杂志,2004,12(10):585-588. 被引量：27
  • 2杨德刚,缪晓辉.对乙型肝炎病毒共价闭合环状DNA的再认识[J].中华医学杂志,2007,87(26):1867-1870. 被引量：7
  • 3European Association for the study of the Liver. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection[J]. J Hepatol,2012,57:167-185.
  • 4Dusheiko G. Treatment of HBeAg positive chronic hepatitis B: interferon or nucleoside analogues[J]. Liver Int,2013,33(Suppl 1): 137- 150.
  • 5Hui CK, Leung N, Yuen ST, et al. Natural history and disease progression in Chinese chronic hepatitis B patients in immunetolerant phase[J]. Hepatology,2007,46:395-401.
  • 6Yuen MF, Lai CL. Treatment of chronic hepatitis B: evolution over twodeeades[J]. J Gsatroenterol Hepatol,2011,26 Suppl 1 : 138-143.
  • 7Hadziyannis S J, Vassilopoulos D, Hadziyannis E. The natural course of chronic hepatitis B virus infection and its management[J]. Adv Pharmacol,2013,67:247-291.
  • 8Ning Q, Han MF, Sun YT, et al. New treatment strategy: switching from long-term entecavir to peginterferon alga-2a induces HBeAg seroconversion/HBsAg clearance in patients with HBeAg-positive chronic hepatitis B[J]. Hepatology,2012,56(Suppl 1):216A.
  • 9Li Q, Dong G, Yu J, et al. Adding peginterferon alfa-2a on nucleos(t) ide analogues therapy improves HBeAg seroconversion and HBsAg decline in HBeAg-positive chronic hepatitis B patients who have achieved virological responses[J]. J Hepatol,2013,58(Suppl 1):S307.
  • 10European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis B[J]. J Hepatol, 2009,50:227-242.

引证文献4

二级引证文献18

中华临床感染病杂志
2013年 第4期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部